Background {#Sec1}
==========

Dermatofibrosarcoma protuberans (DFSP) is a rare skin mesenchymal tumor that usually affects the trunk and extremities. Vulvar DFSP is rare, with fewer than 40 cases previously reported in the literature \[[@CR1], [@CR2]\]. Surgery has been reported as the main therapeutic option for DFSP treatment. However, there is no consensus on margin assessment protocols. The most frequently used techniques are Mohs surgery, wide local excision (WLE) with 2.0 or 3.0 cm margins and surgery followed by three-dimensional complete circumferential and peripheral deep margin assessment (CCPDMA) \[[@CR3]--[@CR6]\].

The CCPDMA technique consists of excising the tumor with a margin smaller than the traditional 3.0-cm one. The specimen is submitted to conventional histologic processing and margins are completely evaluated by the pathologist. Additional study with immunohistochemistry (IHC) may be useful for margin assessment in some doubtful cases. This technique is associated with a more accurate evaluation of the margins and literature reports rates of recurrence lower than 10% \[[@CR5], [@CR7]\].

Another very important aspect of surgery in vulvar DFSP is the clitoris preservation and reconstruction after the lesion is removed, because this directly affects sexuality and quality of life of these patients \[[@CR8], [@CR9]\]. Better results are achieved with a multidisciplinary approach. The objective of this study was to present two cases of vulvar DFSP managed by the Skin Cancer and Gynecology Oncology Departments of AC Camargo Cancer Center with minimal functional damage for the patient. This case report was approved for publication by Fundação Antonio Prudente ethics committee.

Case presentation {#Sec2}
=================

The first case is a 28-year-old female patient referred to us after an incisional biopsy in the vulvar region revealing DFSP. She presented to us with a 5.0-cm lesion in the mons pubis (Figure [1](#Fig1){ref-type="fig"}A). Surgery was indicated, and consisted of a vulvectomy with a local advancement flap as the first approach in order to obtain a 2.0 cm margin from the tumor. Margins were assessed by CCPDMA protocols and they were all free of disease. Therefore, it was possible to avoid clitoris resection.To perform the vulvar reconstruction, a skin expander was placed in the inferior part of the abdominal wall one year after vulvectomy (Figure [1](#Fig1){ref-type="fig"}B). Weekly expansion was performed 3 weeks after the procedure and, in the third month, sufficient skin was attained in this area. The expander was taken out and the inferior 2/3 of the flap was split. The skin of the mons pubis was decorticated and the medium and proximal portions of the flap were advanced to protect the pubis bone. The distal portion was incised horizontally on both sides and folded after, in order to reconstruct the labius majoras (Figure [1](#Fig1){ref-type="fig"}C and D).This patient has been followed for almost 40 months (Figure [1](#Fig1){ref-type="fig"}E). There is no clinical or radiological evidence of recurrence. Regarding the surgery, we considered that a very adequate aesthetic effect was achieved. The patient verbally reported good quality of life, although no quality of life (QOL) questionnaires were applied.The second case is a 57-year-old female patient, also referred to our hospital after an incomplete resection of a DFSP in the vulvar region. She presented to us with a 2.0 cm residual lesion in the right labium major. As the lesion was too close to the clitoris, we performed a 1.0-cm margin instead of the traditional 2.0-cm one, followed by primary closure. The CCPDMA revealed all positive margins except for the upper lateral region of the specimen. The patient was submitted to another WLE of 2.0 cm and subsequent primary closure could be performed once more (Figure [2](#Fig2){ref-type="fig"}A). This patient has been followed for 10 months without any aesthetic or functional issue related to the surgery.Figure 1**Patient 1. (A)** Clinical aspect of the residual lesion of dermatofibrosarcoma protuberans of the vulva before the surgery. **(B)** One year after the first surgery, a skin expander was placed. **(C)** The expander was taken out and the inferior 2/3 of the flap was split. **(D)** the distal portion was incised horizontally on both sides and folded after, in order to reconstruct the labius majoras. **(E)** Follow up after 8 weeks.Figure 2**Patient 2: final clinical aspect of the second surgery when primary closure was performed twice.**

Conclusion {#Sec3}
==========

Regardless being a very rare disease, DFSP in the vulva represents a very challenging situation for the oncologic and plastic surgeons. The resection must follow oncological principles, which sometimes may lead to several aesthetic and functional impacts for the patient due to the difficulty in planning how wide the resection should be \[[@CR4]\]. In this context, reconstructive surgery plays a fundamental role in the management of DFSP patients.

There are just few cases of vulvar DFSP reported in the literature. See Table [1](#Tab1){ref-type="table"} for a summary of previously reported cases of DFSP in the vulva with clinical, treatment and follow-up information. The largest series, from the MD Anderson Cancer Center, reported 13 cases. All of the six cases with positive margins after resection developed tumor recurrence. There was only one relapse between the cases with negative margins after WLE that occurred in a patient showing fibrosarcomatous transformation in the recurrent tumor \[[@CR1]\].Table 1**Summary of the reported cases of Dermatofibrosarcoma Protuberans of the vulva with clinical, treatment and follow up information**AuthorCasesAge, yearsClinical presentationSize, cmInitial treatmentOutcome/follow upEdelweiss and Malpica \[[@CR1]\]136Right labium major mass5Excisional biopsyLR at 12 months. AWD at 16 monthsEdelweiss and Malpica \[[@CR1]\]257Right labium major mass3Excisional biopsyLR at 60 months, then WLE (2x) until negative margin. NED at 216 months.Edelweiss and Malpica \[[@CR1]\]369Mons pubis mass3Excisional biopsy + WLEDead of other causes at 144 monthsEdelweiss and Malpica \[[@CR1]\]448Left paraclitoral mass1.2Excisional biopsy + WLELR, then WLE. NED at 144 months.Edelweiss and Malpica \[[@CR1]\]546Right labium major pigmented lesion4Excisional biopsy + WLE (x2)NED at 84 months.Edelweiss and Malpica \[[@CR1]\]676Right labium major and crural fold mass15Excisional biopsy + WLELR at 7 months, then WLE with negative margin. At 14 months, metastasis to chest wall. At 18 months, metastasis to hip and thigh. Death of the disease at 34 months.Edelweiss and Malpica \[[@CR1]\]744Left labium major mass4Excisional biopsy + WLENED at 53 monthsEdelweiss and Malpica \[[@CR1]\]839Right labium major massN/AWLELR at 48 months. Then, WLE with positive margin. At 60 months, local recurrence. Then WLE with positive margin. Used Gleevec. NED at 72 monthsEdelweiss and Malpica \[[@CR1]\]930Right labium major and mons pubis massN/AExcisional biopsy + WLELR at 11 months. Then, WLE. AWD at 24 monthsEdelweiss and Malpica \[[@CR1]\]1023Right labium major mass4Excisional biopsy + WLENED at 2 monthsEdelweiss and Malpica \[[@CR1]\]1130Left labium major massN/AExcisional biopsyLR at 60 months followed by WLE with positive margin. Then, partial vulvectomy with negative margin. NED at 96 monthsEdelweiss and Malpica \[[@CR1]\]1244Right labium major mass2.5Excisional biopsy + radical vulvectomyNED at 36 monthsEdelweiss and Malpica \[[@CR1]\]1358Paraclitoral mass extending into vagina4.8WLENED at 3 monthsSoltan \[[@CR10]\]1483Left labium major/minor nodule5Excisional biopsyN/AAgress *et al*. \[[@CR11]\]1556Left labium majorN/AExcisional biopsyLR, then WLEBock *et al*. \[[@CR12]\]1652Right mons pruritus8Excisional biopsyLR, then WLEBarnhill *et al*. \[[@CR13]\]1742Right vulva lateral to clitoris nodule1Excisional biopsyLR, then WLE and hemivulvectomyLeake *et al*. \[[@CR14]\]1837Left mons and labium major nodule6.2Excisional biopsyLR, then wide radical excisionLeake *et al*. \[[@CR14]\]1959Right labium major nodule5Excisional biopsyLR, then partial radical vulvectomyPanidis *et al*. \[[@CR15]\]2030Right labium major nodule2WLELR, then radical vulvectomyAartsen and Albus-Lutter \[[@CR16]\]2150N/A1.2Radical vulvectomyN/AKarlen *et al*. \[[@CR17]\]2236Left labium major irritated lump5WLEN/ANirenberg *et al*. \[[@CR18]\]2341Left labium major lump8WLEN/AAlverez-Canas \[[@CR19]\]2458Left labium major mass3.2WLEN/ASoergel *et al*. \[[@CR20]\]2547Left vulva mass + lung metastasis3Partial radical vulvectomy + chemotherapyLR, then WLE + radiotherapyGhorbani *et al*. \[[@CR21]\]2647Left paraclitoral areaN/AHemivulvectomyLR, then wide radical excisionGhorbani *et al*. \[[@CR21]\]2744Left labium major mass4Wide radical excisionN/AGhorbani *et al*. \[[@CR21]\]2866Mons mass1.5WLEN/AGhorbani *et al*. \[[@CR21]\]2936Right labium mass5Excsional biopsyN/AMoodley and Moodley \[[@CR22]\]3039Left labium major mass12WLEN/AVanni *et al*. \[[@CR23]\]3139Inferior vulva/perineum mass6WLEN/AKholova *et al*. \[[@CR24]\]3231Left labium major recurrent nodule1.5Excisional biopsyLR, then WLE + radiotherapyOhlinger *et al*. \[[@CR25]\]3336Left vulva nodule2.8Excisional biopsyLR, then WLEHancox *et al*. \[[@CR26]\]3455Right labium major mass8MMSNEDHammonds and Hendi \[[@CR6]\]3559Right labium major mass4MMSNEDDoufekas *et al*. \[[@CR3]\]3639Left labium major noduleN/AIncisional biopsyMMS with primary closure. NED at 3 yearsZizi-Sermpetzoglou *et al*. \[[@CR27]\]3766Mons pubisN/AWLENEDN/A, not available; WLE, wide local excision; MMS, Mohs micrographic surgery; LR, local recurrence; AWD, alive with disease; AWOD, alive without disease; NED, no evidence of disease).

Based on this paper, the role of an adequate assessment of margins in these cases can be assumed. In our service, the protocol is to submit the specimen to conventional histologic processing with complete evaluation of the margins by CCPDMA by the pathologist, and IHC study whenever necessary \[[@CR2], [@CR5]\]. The morphologic and molecular pathologic findings of vulvar DFSP are quite similar to DFSP in other sites, including the frequent finding of the fusion between collagen type I alpha 1 gene (COL1A1) on chromosome 17 and the platelet-derived growth factor B-chain (PDGFB) gene on chromosome 22 \[[@CR23], [@CR28]\].

There is also scarce literature on reconstructive options in vulvar DFSP. There are two recent reports on Mohs surgery for vulvar DFSP, and both were submitted to primary closure \[[@CR3], [@CR6]\]. No data related to clitoris preservation or major vulvar reconstructions have been found.

Skin expansions are often used to reconstruct burned areas or breasts after a mastectomy or to hide scars \[[@CR29]\]. Although there is no strong evidence in the literature to supports its use in skin tumors, we believe that it can be safely used since the tumor resection is not delayed because of the use of the expansion. Also, in our case we have had a very rigorous assessment of the pathological margins to ensure that the resection was complete. Moreover, the patient was kept for over a year in clinical follow up before starting the expansion.

Our first case illustrates an example of a major vulvar reconstruction using skin expansion followed by a skin and fat tissue flap. Although it has been done in only one patient, the clinical outcome suggests this can be a feasible option in such cases. Both our patients were submitted to clitoris-sparing surgery, which was only possible due to the utilization of the CCPDMA protocol by our Pathology Department.

We conclude that vulvar DFSP, although a very challenging lesion that usually implies difficult surgical management, if treated in a multidisciplinary environment with surgical oncologists, experienced pathologists and reconstructive surgeons, can achieve good results. And even in difficult cases that present with large lesions and compromising challenging areas, a complete oncologicresection can be performed, minimizing functional damage for the patient.
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DFSP

:   dermatofibrosarcoma protuberans

WLE

:   wide local excision

CCPDMA

:   3-dimensional complete circumferential and peripheral deep margin assessment

IHC

:   immunohistochemistry

COL1A1

:   collagen type I alpha 1

PGDF

:   Platelet-derived growth factor B-chain.
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